Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial

NCT02063100 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT02063100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02063100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2014
Completion date
Not reported
Enrollment
720 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, proteinuria